FIGS, Inc. (FIGS) Stock Analysis
Is FIGS a good investment?
FIGS, Inc. (FIGS) has a Plutrex AI rating of 68.5/100 as of November 11, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability moat: Gross margin of 67.4% is 11.8 points above the industry average (55.6%), net margin of 9.67% is 2.4x peers (4.08%), and ROE of 16.75% exceeds peers (12.71%) — all achieved with virtually zero debt (D/E 0.13 vs. industry 0.98), confirming genuine operational superiority rather than financial engineering.. Main concern: Egregious near-term valuation mismatch: P/E of 59.43 is 155.9% above the industry average of 23.23, yet next-year EPS growth of 5.15% is 61.1% BELOW the industry average of 13.26%. Peers growing earnings 2.6x faster than FIGS are priced at a fraction of its multiple. Even applying a generous quality premium of 40-45x earnings to fair value, the stock is 30-40% overvalued at $22.39, with intrinsic value estimated at $13-$18..
Investment Summary
FIGS is a genuinely exceptional consumer apparel business — gross margins of 67.4% (vs. industry avg 55.6%), net margins of 9.67% (vs. industry avg 4.1%), debt-to-equity of 0.13 (vs. industry avg 0.98), $331M in cash, and $148M in annual free cash flow. ROE of 16.75% achieved with virtually zero leverage is a hallmark of operational excellence. The news backdrop is unambiguously positive: net profit doubled in Q3, earnings estimates are being revised upward by analysts, and the company is showing consistent ability to beat estimates. The 'Why Figs Stock Popped Today' headline and Q3 2026 earnings call transcript confirm accelerating operational momentum. The '3 Key Takeaways for Long-Term Investors' article reinforces the durable investment case. HOWEVER, the central problem is valuation: the P/E of 59.43 is 155.9% above the industry average of 23.23, while next-year EPS growth of only 5.15% is 61.1% BELOW the industry average of 13.26%. Paying 60x earnings for near-term 5% EPS growth is extremely difficult to rationalize. The business deserves a premium, but perhaps 40-45x earnings — implying fair value closer to $15-$18. At $22.39, the stock requires near-perfect execution of the 5-year 35.24% EPS growth re-acceleration narrative with no margin for disappointment.
Key Strengths
- Exceptional profitability moat: Gross margin of 67.4% is 11.8 points above the industry average (55.6%), net margin of 9.67% is 2.4x peers (4.08%), and ROE of 16.75% exceeds peers (12.71%) — all achieved with virtually zero debt (D/E 0.13 vs. industry 0.98), confirming genuine operational superiority rather than financial engineering.
- Fortress balance sheet with positive news momentum: $331M in cash, $148M annual free cash flow, and essentially no debt provide extreme financial optionality. Q3 2026 results showing net profit doubling and upward earnings estimate revisions from analysts confirm accelerating operational execution and sustainable cash generation.
- Superior long-term growth trajectory: 5-year forward EPS growth of 35.24% is 135.6% above the industry average of 14.96%, revenue growth of 25.7% is 2.4x peers — if the re-acceleration narrative materializes, the 5-year PEG of 1.69 offers modest premium to the industry's 1.89, partially validating the long-term bull case.
Key Concerns
- Egregious near-term valuation mismatch: P/E of 59.43 is 155.9% above the industry average of 23.23, yet next-year EPS growth of 5.15% is 61.1% BELOW the industry average of 13.26%. Peers growing earnings 2.6x faster than FIGS are priced at a fraction of its multiple. Even applying a generous quality premium of 40-45x earnings to fair value, the stock is 30-40% overvalued at $22.39, with intrinsic value estimated at $13-$18.
- Growth re-acceleration execution risk: The 5-year EPS growth target of 35.24% requires years 2 through 5 to average 44%+ EPS growth after a 5.15% next year — a dramatic re-acceleration that embeds heroic assumptions. The 55.8-point spread between gross margin (67.4%) and operating margin (11.6%) confirms heavy SG&A infrastructure; if this cost base doesn't scale efficiently, the re-acceleration fails and the PEG advantage evaporates.
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
FIGS scores exceptionally on profitability and health but poorly on valuation. Gross margin of 67.4% is 11.8 percentage points above the industry average of 55.6% — an extraordinary competitive moat in apparel. Net margin of 9.67% is 2.4x the industry average of 4.08%, confirming elite profit conversion. ROE of 16.75% exceeds the industry average of 12.71% by 31.8%, critically achieved with D/E of only 0.13 vs. the industry's 0.98 — meaning FIGS generates superior returns without leverage. Operating margin of 11.65% is essentially flat vs. the industry average of 11.79%, revealing the gross margin advantage is fully consumed by above-average SG&A — a 55.8-point spread between gross (67.4%) and operating (11.6%) margins signals heavy cost infrastructure. Historical revenue growth of 25.7% (2.4x the industry's 10.6%) and earnings growth of 100% (2.6x the industry's 38.1%) are exceptional. The critical concern: forward next-year EPS growth of 5.15% is only 39% of the industry average of 13.26%. P/E of 59.43 at 155.9% premium to the industry's 23.23 on a growth basis that lags peers is the most acute valuation risk. PEG of 1.69 (vs. industry 1.89) using the 5-year 35.24% EPS growth rate offers a marginal 10.9% discount — the only valuation metric where FIGS looks reasonable, but only if the 5-year growth materializes.
News Sentiment
FIGS is having a moment — and Wall Street is taking notice. The medical scrubs company behind the premium healthcare workwear brand just delivered a standout third quarter that sent its stock jumping, with net profit doubling year-over-year and analysts scrambling to revise their earnings estimates higher. The 'Why Figs Stock Popped Today' headline tells the story in a nutshell: a business that's executing at a high level in a challenging environment for growth stocks. The Q3 2026 Earnings Call Transcript reveals a company that's quietly transforming into a profitable powerhouse — not just a trendy direct-to-consumer brand burning cash to grow. What makes this especially impressive is context: growth stocks broadly have faced headwinds, yet FIGS managed to stand out. The '3 Key Takeaways for Long-Term Investors' piece underscores what experienced investors are focusing on — the durable competitive advantages of a brand deeply embedded in healthcare professionals' daily lives. And with earnings estimates moving up, not down, this isn't a one-quarter wonder. The pattern of consistently beating analyst expectations suggests management may be setting a deliberately conservative bar — a hallmark of companies that become long-term compounders. The bull case for FIGS is real and getting stronger operationally. The debate isn't about business quality — it's entirely about price. For investors who can get in at the right valuation, this is the kind of brand story that plays out over a decade.
Risk Assessment
PRIMARY RISK: Valuation compression. At 59.43x earnings with 5.15% near-term EPS growth, any disappointment in the re-acceleration narrative could trigger multiple compression from 59x toward the industry's 23x, implying potential 50%+ downside from current levels independent of any fundamental deterioration. SECONDARY RISK: Operating leverage failure — the 55.8-point gross-to-operating margin spread suggests SG&A must scale efficiently for the 35.24% 5-year EPS growth to materialize; if volume growth slows, fixed cost leverage disappears. MITIGATING FACTORS: (1) $331M cash and $148M FCF provide a defensive floor — the company can buy back stock, make acquisitions, or fund growth without dilution; (2) positive Q3 momentum (net profit doubled) reduces near-term fundamental risk; (3) analyst estimate revisions are upward, suggesting the near-term may beat the modest 5.15% forward growth bar. MITIGATION STRATEGY: Wait for valuation compression toward $16.50-$18.50 (40-45x fair-value earnings multiple on current EPS) before initiating; this addresses the central risk mathematically and creates adequate margin of safety.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is FIGS a halal stock?
No, FIGS, Inc. (FIGS) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for FIGS?
FIGS, Inc. (FIGS) has a Plutrex AI rating of 68.5/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is FIGS a good investment?
According to Plutrex AI, FIGS has a Buy rating (68.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in FIGS?
US stocks like FIGS can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in FIGS?
Plutrex AI identifies the main risks for FIGS by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.